This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INSY INSYS Therapeutics (INSY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About INSYS Therapeutics Stock (NASDAQ:INSY) 30 days 90 days 365 days Advanced Chart Get INSYS Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.23▼$65,799,000.0052-Week Range N/AVolumeN/AAverage Volume9.52 million shsMarket Capitalization$21.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. Read More Receive INSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INSY Stock News HeadlinesFederal Indictment Against NJ Doctor Collapses in Stunning DOJ Reversal, as Obtained by Health Law AllianceMay 21, 2025 | morningstar.comMLarge Granular Lymphocyte Leukemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 23, 2025 | theglobeandmail.comUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake. | Stansberry Research (Ad)Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 15, 2025 | theglobeandmail.comAlly Financial Inc. (ALLY): Among the Dividend Giants with Lowest Short Interest in 2024September 25, 2024 | msn.comARS Pharmaceuticals: A Decent Bet For Upside After Neffy ApprovalSeptember 6, 2024 | seekingalpha.comMore than half a billion opioid pills in 14 years: How prescriptions contributed to a crisis in BaltimoreAugust 3, 2024 | msn.comAldeyra Therapeutics, Inc. (ALDX)May 7, 2024 | finance.yahoo.comSee More Headlines INSY Stock Analysis - Frequently Asked Questions How were INSYS Therapeutics' earnings last quarter? INSYS Therapeutics, Inc. (NASDAQ:INSY) released its quarterly earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.33. INSYS Therapeutics's revenue was down 68.1% on a year-over-year basis. When did INSYS Therapeutics' stock split? INSYS Therapeutics's stock split on the morning of Monday, March 31st 2014.The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split. What other stocks do shareholders of INSYS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN). Company Calendar Last Earnings5/10/2019Today7/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CIK1516479 Webwww.insysrx.com Phone480-500-3127FaxN/AEmployees226Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.51 million Net Margins-346.61% Pretax MarginN/A Return on Equity-1,430.37% Return on Assets-64.04% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.50 Sales & Book Value Annual Sales$82.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / BookN/AMiscellaneous Outstanding Shares74,570,000Free FloatN/AMarket Cap$21.71 million OptionableOptionable Beta3.21 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:INSY) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INSYS Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INSYS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.